By using this website you agree that we use cookies. You can find out more in the privacy policy.

Arizona Tribune - Aytu BioPharma to Present at Upcoming October 2025 Conferences

Arizona Tribune
×
NYSE - LSE
RBGPF -19.57% 69 $
CMSD 0.18% 22.63 $
RELX -0.12% 33.3 $
RIO 1.15% 98.26 $
VOD -1.02% 15.69 $
NGG -0.03% 90.29 $
AZN -0.47% 204.03 $
BCE -2.31% 23.35 $
GSK -0.26% 58.21 $
CMSC 0.18% 22.43 $
RYCEF -1.59% 16.96 $
BTI -0.07% 58.81 $
BCC -0.51% 80.17 $
JRI 0.31% 13.02 $
BP 1.16% 46.44 $
Aytu BioPharma to Present at Upcoming October 2025 Conferences
Aytu BioPharma to Present at Upcoming October 2025 Conferences

Aytu BioPharma to Present at Upcoming October 2025 Conferences

BOULEVARD 10.10.2025

DENVER, CO / ACCESS Newswire / October 10, 2025 / DENVER, CO / ACCESS Newswire / October 10, 2025 /Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:

Text size:

2025 Maxim Growth Summit

Date: October 22, 2025
Location: New York City

Investors should reach out to their Maxim sales representatives, or Robert Blum of Lytham Partners at [email protected] to schedule one-on-one meetings with Aytu's management.

Planet MicroCap Showcase: TORONTO 2025

Date: October 22, 2025 - October 23, 2025
Location: Toronto
Presentation Time: 2:30 p.m. Eastern time
Webcast: https://event.summitcast.com/view/34SFNFBix4cZpKNiohrXeh/eV26zB4GZpybjQPU4g6xja

If you would like to schedule one-on-one investor meetings with Aytu's management, and to attend the Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClub, please register here: REGISTER. Conversely, you can contact Robert Blum of Lytham Partners at [email protected] to assist in coordination.

About Aytu BioPharma

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.

Contacts for Investors

Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]

Robert Blum
Lytham Partners
[email protected]

SOURCE: Aytu BioPharma, Inc.



View the original press release on ACCESS Newswire

A.Anderson--AT

Featured

In fiery speech, Pope Leo says 'Enough to war!'

In fiery speech, Pope Leo says 'Enough to war!'
Benin leans into painful past to attract tourists

Benin leans into painful past to attract tourists

Panic buttons, undercover cops: How Peru bus drivers try to stay safe

Panic buttons, undercover cops: How Peru bus drivers try to stay safe
Court Rules Against Jason Shurka in EESystem Case; $54,034 in Federal Sanctions Ordered

Court Rules Against Jason Shurka in EESystem Case; $54,034 in Federal Sanctions Ordered